var data={"title":"Overview of the acute management of tachyarrhythmias","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Overview of the acute management of tachyarrhythmias</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/overview-of-the-acute-management-of-tachyarrhythmias/contributors\" class=\"contributor contributor_credentials\">Jordan M Prutkin, MD, MHS, FHRS</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/overview-of-the-acute-management-of-tachyarrhythmias/contributors\" class=\"contributor contributor_credentials\">James Hoekstra, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/overview-of-the-acute-management-of-tachyarrhythmias/contributors\" class=\"contributor contributor_credentials\">Hugh Calkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/overview-of-the-acute-management-of-tachyarrhythmias/contributors\" class=\"contributor contributor_credentials\">Brian C Downey, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/overview-of-the-acute-management-of-tachyarrhythmias/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 28, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tachyarrhythmias, defined as abnormal heart rhythms with a ventricular rate of 100 or more beats per minute, are frequently symptomatic and often result in patients seeking care at their provider's office or the emergency department. Signs and symptoms related to the tachyarrhythmia may include shock, hypotension, heart failure, shortness of breath, chest pain, acute myocardial infarction, palpitations, <span class=\"nowrap\">and/or</span> decreased level of consciousness. An overview of the management of these various arrhythmias will be presented here. More complete reviews of the individual arrhythmias are discussed separately.</p><p class=\"headingAnchor\" id=\"H1040743\"><span class=\"h1\">INITIAL DIAGNOSTIC AND TREATMENT DECISIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In anyone who presents with a symptomatic tachyarrhythmia, a 12-lead electrocardiogram (ECG) should be obtained while a brief initial assessment of the patient's overall clinical assessment is performed. If the patient is hemodynamically unstable, it may be preferable to obtain only a rhythm strip prior to urgent cardioversion and not wait for a 12-lead ECG. The information acquired from these initial assessments is crucial for subsequent management of the patient.</p><p class=\"headingAnchor\" id=\"H1040751\"><span class=\"h2\">Is the patient clinically (or hemodynamically) unstable?</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most important clinical determination in a patient presenting with a tachyarrhythmia is whether or not the patient is experiencing signs and symptoms related to the rapid heart rate. These can include hypotension, shortness of breath, chest pain suggestive of coronary ischemia, shock, <span class=\"nowrap\">and/or</span> decreased level of consciousness. </p><p>Determining whether a patient's symptoms are related to the tachycardia depends upon several factors, including age and the presence of underlying cardiac disease.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemodynamically unstable and not sinus rhythm &ndash; If a patient has clinically significant hemodynamic instability potentially due to the tachyarrhythmia, an attempt should be made as quickly as possible to determine whether the rhythm is sinus tachycardia (<a href=\"image.htm?imageKey=CARD%2F109811\" class=\"graphic graphic_algorithm graphicRef109811 \">algorithm 1</a>). If the rhythm is not sinus tachycardia, or if there is any doubt that the rhythm is sinus tachycardia, <strong>urgent conversion </strong>to sinus rhythm is recommended. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-evaluation-of-narrow-qrs-complex-tachycardias#H17\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias&quot;, section on 'Similar to sinus rhythm'</a> and <a href=\"topic.htm?path=basic-principles-and-technique-of-electrical-cardioversion-and-defibrillation\" class=\"medical medical_review\">&quot;Basic principles and technique of electrical cardioversion and defibrillation&quot;</a> and <a href=\"topic.htm?path=approach-to-the-diagnosis-of-wide-qrs-complex-tachycardias#H601165872\" class=\"medical medical_review\">&quot;Approach to the diagnosis of wide QRS complex tachycardias&quot;, section on 'Assessment of stability'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemodynamically stable &ndash; If the patient is not experiencing hemodynamic instability, a nonemergent approach to the diagnosis of the patient's rhythm can be undertaken [<a href=\"https://www.uptodate.com/contents/overview-of-the-acute-management-of-tachyarrhythmias/abstract/1,2\" class=\"abstract_t\">1,2</a>]. A close examination of the 12-lead ECG should permit the correct identification of the arrhythmia in 80 percent of cases [<a href=\"https://www.uptodate.com/contents/overview-of-the-acute-management-of-tachyarrhythmias/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"#H1040758\" class=\"local\">'Is the QRS complex narrow or wide? Regular or irregular?'</a> below and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-evaluation-of-narrow-qrs-complex-tachycardias#H684866\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias&quot;, section on 'Evaluation'</a> and <a href=\"topic.htm?path=approach-to-the-diagnosis-of-wide-qrs-complex-tachycardias#H16\" class=\"medical medical_review\">&quot;Approach to the diagnosis of wide QRS complex tachycardias&quot;, section on 'Evaluation of the electrocardiogram'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1040758\"><span class=\"h2\">Is the QRS complex narrow or wide? Regular or irregular?</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of any tachyarrhythmia depends on a variety of clinical factors. However, most treatment decisions are made based on the width, morphology, and regularity of the QRS complex. In most patients, the differentiation between narrow and wide QRS complex tachyarrhythmias requires only a surface ECG.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Narrow QRS complex tachyarrhythmias have a QRS complex &lt;120 milliseconds in duration</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Wide QRS complex tachyarrhythmias have a QRS complex &ge;120 milliseconds in duration </p><p/><p>The various types of narrow and wide QRS complex tachyarrhythmias are discussed below. (See <a href=\"#H1041109\" class=\"local\">'Narrow QRS complex tachyarrhythmias'</a> below and <a href=\"#H14\" class=\"local\">'Wide QRS complex tachyarrhythmias'</a> below.)</p><p class=\"headingAnchor\" id=\"H1041109\"><span class=\"h1\">NARROW QRS COMPLEX TACHYARRHYTHMIAS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Discussion of the treatment of narrow QRS complex tachycardias will be divided into those with a regular ventricular response and those with an irregular ventricular response (<a href=\"image.htm?imageKey=CARD%2F76920\" class=\"graphic graphic_algorithm graphicRef76920 \">algorithm 2</a> and <a href=\"image.htm?imageKey=CARD%2F109811\" class=\"graphic graphic_algorithm graphicRef109811 \">algorithm 1</a>).</p><p class=\"headingAnchor\" id=\"H1041227\"><span class=\"h2\">Regular narrow QRS complex tachyarrhythmias</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The regular narrow QRS complex tachycardias include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sinus tachycardia (see <a href=\"topic.htm?path=sinus-tachycardia-evaluation-and-management\" class=\"medical medical_review\">&quot;Sinus tachycardia: Evaluation and management&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inappropriate sinus tachycardia (see <a href=\"topic.htm?path=sinus-tachycardia-evaluation-and-management#H253189891\" class=\"medical medical_review\">&quot;Sinus tachycardia: Evaluation and management&quot;, section on 'Inappropriate sinus tachycardia'</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sinoatrial nodal reentrant tachycardia (SANRT) (see <a href=\"topic.htm?path=sinoatrial-nodal-reentrant-tachycardia-sanrt\" class=\"medical medical_review\">&quot;Sinoatrial nodal reentrant tachycardia (SANRT)&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atrioventricular nodal reentrant tachycardia (AVNRT) (see <a href=\"topic.htm?path=atrioventricular-nodal-reentrant-tachycardia\" class=\"medical medical_review\">&quot;Atrioventricular nodal reentrant tachycardia&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atrioventricular reentrant (or reciprocating) tachycardia (AVRT) (see <a href=\"topic.htm?path=atrioventricular-reentrant-tachycardia-avrt-associated-with-an-accessory-pathway\" class=\"medical medical_review\">&quot;Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atrial tachycardia (AT) (see <a href=\"topic.htm?path=focal-atrial-tachycardia\" class=\"medical medical_review\">&quot;Focal atrial tachycardia&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atrial flutter (see <a href=\"topic.htm?path=overview-of-atrial-flutter\" class=\"medical medical_review\">&quot;Overview of atrial flutter&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intraatrial reentrant tachycardia (IART) (see <a href=\"topic.htm?path=intraatrial-reentrant-tachycardia\" class=\"medical medical_review\">&quot;Intraatrial reentrant tachycardia&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Junctional ectopic tachycardia </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nonparoxysmal junctional tachycardia</p><p/><p>Because the vast majority of regular narrow QRS complex tachycardias are due to sinus tachycardia, AVNRT, AVRT, AT, and atrial flutter, these conditions will be presented here. Discussions regarding the treatment of the other less common types of regular narrow QRS complex tachycardias are presented separately. (See <a href=\"topic.htm?path=sinus-tachycardia-evaluation-and-management#H10\" class=\"medical medical_review\">&quot;Sinus tachycardia: Evaluation and management&quot;, section on 'Inappropriate sinus tachycardia'</a> and <a href=\"topic.htm?path=sinoatrial-nodal-reentrant-tachycardia-sanrt#H6\" class=\"medical medical_review\">&quot;Sinoatrial nodal reentrant tachycardia (SANRT)&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=intraatrial-reentrant-tachycardia#H4\" class=\"medical medical_review\">&quot;Intraatrial reentrant tachycardia&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=treatment-of-symptomatic-arrhythmias-associated-with-the-wolff-parkinson-white-syndrome#H13208282\" class=\"medical medical_review\">&quot;Treatment of symptomatic arrhythmias associated with the Wolff-Parkinson-White syndrome&quot;, section on 'Permanent junctional reciprocating tachycardia'</a>.)</p><p class=\"headingAnchor\" id=\"H30456082\"><span class=\"h3\">Sinus tachycardia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common tachycardia is sinus tachycardia. If it is certain that the patient's rhythm is sinus tachycardia and clinically significant cardiac symptoms are present, management should be focused on the underlying cardiac disorder and on treating any contributing cause of the rapid heart rate (eg, coronary ischemia, pulmonary embolism, respiratory or cardiac failure, hypovolemia, anemia, hyperthyroidism, fever, pain, or anxiety). This may include volume replacement or diuresis, antibiotics, anti-pyretics, oxygen, pain control, or other treatments as appropriate. In patients with sinus tachycardia and certain forms of heart disease, such as coronary disease or aortic stenosis, treatment may need to be directed at the heart rate itself. In such cases, cautious use of an intravenous beta blocker is appropriate (eg, <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a> 5 mg intravenously every five minutes until the heart rate is controlled, to a total of 15 mg, followed by an oral regimen). (See <a href=\"topic.htm?path=sinus-tachycardia-evaluation-and-management\" class=\"medical medical_review\">&quot;Sinus tachycardia: Evaluation and management&quot;</a> and <a href=\"topic.htm?path=acute-myocardial-infarction-role-of-beta-blocker-therapy\" class=\"medical medical_review\">&quot;Acute myocardial infarction: Role of beta blocker therapy&quot;</a> and <a href=\"topic.htm?path=medical-management-of-symptomatic-aortic-stenosis\" class=\"medical medical_review\">&quot;Medical management of symptomatic aortic stenosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H30456175\"><span class=\"h3\">Atrioventricular nodal reentrant tachycardia (AVNRT)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with AVNRT associated with hemodynamic compromise or severe symptoms due to the tachycardia (eg, angina, hypotension, or heart failure) require rapid termination of the arrhythmia. (See <a href=\"topic.htm?path=atrioventricular-nodal-reentrant-tachycardia#H21\" class=\"medical medical_review\">&quot;Atrioventricular nodal reentrant tachycardia&quot;, section on 'Initial management'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with AVNRT who are hemodynamically unstable related to their arrhythmia, we recommend immediate DC cardioversion. Consideration for using vagal maneuvers (Valsalva maneuver or carotid sinus massage) is also reasonable if it does not delay cardioversion. (See <a href=\"topic.htm?path=vagal-maneuvers\" class=\"medical medical_review\">&quot;Vagal maneuvers&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with AVNRT associated with severe symptoms due to the tachycardia (eg, angina, hypotension, heart failure, or mental status changes) in whom intravenous access is available, we suggest an initial attempt at termination with <a href=\"topic.htm?path=adenosine-drug-information\" class=\"drug drug_general\">adenosine</a> rather than cardioversion. If adenosine cannot be administered or is ineffective, patients should undergo immediate DC cardioversion.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with AVNRT that is not associated with severe symptoms or hemodynamic collapse, including patients without symptoms, we suggest the following sequential approach to acute termination:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Vagal maneuvers (see <a href=\"topic.htm?path=vagal-maneuvers\" class=\"medical medical_review\">&quot;Vagal maneuvers&quot;</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>IV <a href=\"topic.htm?path=adenosine-drug-information\" class=\"drug drug_general\">adenosine</a></p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>IV non-dihydropyridine calcium channel blocker or an IV beta blocker</p><p/><p class=\"headingAnchor\" id=\"H30456182\"><span class=\"h3\">Atrioventricular reentrant tachycardia (AVRT)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with any arrhythmia (ie, orthodromic AVRT, antidromic AVRT, atrial <span class=\"nowrap\">fibrillation/flutter)</span> involving an accessory pathway should have a prompt initial assessment of hemodynamic status. AVRT may result in either a narrow QRS complex tachycardia or a wide QRS complex tachycardia depending on the direction of conduction across the accessory pathway and also the presence of aberrant conduction. (See <a href=\"#H540969891\" class=\"local\">'Antidromic AVRT'</a> below and <a href=\"topic.htm?path=treatment-of-symptomatic-arrhythmias-associated-with-the-wolff-parkinson-white-syndrome#H9925775\" class=\"medical medical_review\">&quot;Treatment of symptomatic arrhythmias associated with the Wolff-Parkinson-White syndrome&quot;, section on 'Acute treatment of symptomatic arrhythmias'</a>.) <br/></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with AVRT who are hemodynamically unstable related to their arrhythmia, we recommend immediate DC cardioversion. Consideration for using vagal maneuvers is reasonable if it does not delay cardioversion. (See <a href=\"topic.htm?path=vagal-maneuvers\" class=\"medical medical_review\">&quot;Vagal maneuvers&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with acute symptomatic <strong>orthodromic</strong> AVRT (usually narrow QRS complex in the absence of an underlying conduction delay) who are hemodynamically stable, our approach is as follows (<a href=\"image.htm?imageKey=CARD%2F62762\" class=\"graphic graphic_table graphicRef62762 \">table 1</a>):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We recommend initial treatment with one or more vagal maneuvers rather than pharmacologic therapy. (See <a href=\"topic.htm?path=vagal-maneuvers\" class=\"medical medical_review\">&quot;Vagal maneuvers&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If vagal maneuvers are ineffective, pharmacologic therapy with an AV nodal blocking agent (ie, <a href=\"topic.htm?path=adenosine-drug-information\" class=\"drug drug_general\">adenosine</a>, <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>, beta blockers) should be instituted. We suggest intravenous adenosine rather than intravenous verapamil as the initial choice based on its high efficacy and short half-life. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If <a href=\"topic.htm?path=adenosine-drug-information\" class=\"drug drug_general\">adenosine</a> is ineffective, we proceed with intravenous <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a> as the second-line agent. If orthodromic AVRT persists, intravenous <a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">procainamide</a> and beta blockers approved for intravenous administration (<a href=\"topic.htm?path=propranolol-drug-information\" class=\"drug drug_general\">propranolol</a>, <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a>, and <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a>) are additional therapeutic options. <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">Amiodarone</a> may also be considered.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Because most patients with acute symptomatic <strong>antidromic</strong> AVRT have a wide QRS complex, the approach to this arrhythmia is discussed below. (See <a href=\"#H540969891\" class=\"local\">'Antidromic AVRT'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H30456218\"><span class=\"h3\">Atrial tachycardia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Focal atrial tachycardias (AT), usually paroxysmal and self-limited, arise from a single site or area of microreentry outside of the sinus node. (See <a href=\"topic.htm?path=focal-atrial-tachycardia#H16\" class=\"medical medical_review\">&quot;Focal atrial tachycardia&quot;, section on 'Acute treatment'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with AT who are felt to be hemodynamically unstable related to their arrhythmia, we recommend immediate DC cardioversion.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For a hemodynamically stable patient with symptomatic AT, we suggest acute treatment with an oral or intravenous beta blocker or non-dihydropyridine calcium channel blocker (ie, <a href=\"topic.htm?path=diltiazem-drug-information\" class=\"drug drug_general\">diltiazem</a> or <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>). Such treatment may slow the ventricular response <span class=\"nowrap\">and/or</span> terminate the arrhythmia. Intravenous <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a> is an acceptable alternative that may be preferred in a patient with borderline hypotension as amiodarone may slow the rate or convert the rhythm back to normal sinus.</p><p/><p class=\"headingAnchor\" id=\"H540969608\"><span class=\"h3\">Atrial flutter</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Atrial flutter usually presents as a regular narrow complex tachycardia, though it occasionally may have an irregular ventricular response. Atrial flutter should always be considered high on the differential diagnosis when a patient presents with a regular narrow complex tachycardia with a ventricular response of approximately 150 beats per minute. As with atrial fibrillation, the early steps in the management of a patient with new onset atrial flutter involve an assessment of the need for cardioversion, ventricular rate slowing therapy, and antithrombotic therapy. Our initial approach to the management of patients with atrial flutter is the same as our approach for atrial fibrillation. (See <a href=\"#H8336616\" class=\"local\">'Atrial fibrillation'</a> below.)</p><p class=\"headingAnchor\" id=\"H30456299\"><span class=\"h2\">Irregular narrow QRS complex tachyarrhythmias</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The irregular narrow QRS complex tachycardias include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atrial fibrillation (AF) (see <a href=\"topic.htm?path=overview-of-atrial-fibrillation\" class=\"medical medical_review\">&quot;Overview of atrial fibrillation&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atrial flutter with variable conduction (see <a href=\"topic.htm?path=overview-of-atrial-flutter\" class=\"medical medical_review\">&quot;Overview of atrial flutter&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multifocal atrial tachycardia (MAT) (see <a href=\"topic.htm?path=multifocal-atrial-tachycardia\" class=\"medical medical_review\">&quot;Multifocal atrial tachycardia&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H8336616\"><span class=\"h3\">Atrial fibrillation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with new onset (ie, first detected or diagnosed) AF with a rapid rate present with symptoms related to the arrhythmia. Except for embolization, the symptoms associated with new onset AF are primarily due to a rapid and irregular ventricular response. The early steps in the management of a patient with new onset rapid AF involve an assessment of the need for cardioversion, ventricular rate slowing therapy, and antithrombotic therapy. (See <a href=\"topic.htm?path=management-of-new-onset-atrial-fibrillation#H461234558\" class=\"medical medical_review\">&quot;Management of new onset atrial fibrillation&quot;, section on 'Summary and recommendations'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Urgent or emergent cardioversion should be considered for patients with active ischemia, significant hypotension, severe heart failure, or the presence of a preexcitation syndrome associated with rapid conduction using the accessory pathway. (See <a href=\"#H30456182\" class=\"local\">'Atrioventricular reentrant tachycardia (AVRT)'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For all patients who do not require urgent or emergent cardioversion, we recommend rate control to improve symptoms and to reduce the risk of tachycardia-mediated cardiomyopathy. We believe a goal of less than 110 beats per minute is reasonable. Beta blockers and non-dihydropyridine calcium channel blockers are preferred as first-line agents in most patients, and <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">digoxin</a> may be considered a second-line or adjunct medication. Intravenous preparations are preferred to oral preparations when rapid control of rate is necessary.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with AF less than 48 hours in duration in whom cardioversion is planned, the use of antithrombotic therapy pre-cardioversion to reduce the risk of embolization can be considered.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with AF longer than 48 hours in duration (or of unknown duration), we recommend four weeks of therapeutic oral anticoagulation prior to cardioversion, as opposed to immediate cardioversion. Transesophageal echocardiography-based (TEE) screening for the presence of atrial thrombi is recommended if cardioversion is desired earlier than four weeks. Anticoagulation must be continued for a minimum of four weeks after cardioversion. Whether long-term anticoagulation is indicated depends on assessment of the patient's thromboembolic risk profile. (See <a href=\"topic.htm?path=atrial-fibrillation-risk-of-embolization\" class=\"medical medical_review\">&quot;Atrial fibrillation: Risk of embolization&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H636766958\"><span class=\"h3\">Atrial flutter</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As with atrial fibrillation, the early steps in the management of a patient with new onset atrial flutter involve an assessment of the need for cardioversion, ventricular rate slowing therapy, and antithrombotic therapy. Our initial approach to the management of patients with atrial flutter is the same as our approach for atrial fibrillation. (See <a href=\"#H8336616\" class=\"local\">'Atrial fibrillation'</a> above.)</p><p class=\"headingAnchor\" id=\"H8336630\"><span class=\"h3\">Multifocal atrial tachycardia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multifocal atrial tachycardia (MAT) is an arrhythmia with organized atrial activity yielding P waves with three or more different morphologies. MAT is commonly associated with significant underlying pulmonary or cardiac illness. (See <a href=\"topic.htm?path=multifocal-atrial-tachycardia#H754560\" class=\"medical medical_review\">&quot;Multifocal atrial tachycardia&quot;, section on 'Treatment'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most episodes of MAT do not precipitate hemodynamic compromise or limiting symptoms. Thus, therapy in patients with MAT should be aimed at the inciting underlying disease.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with MAT and associated hypokalemia or hypomagnesemia should undergo electrolyte repletion prior to the initiation of additional medical therapy for MAT.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Medical therapy for MAT is indicated only if MAT causes a sustained rapid ventricular response that causes or worsens myocardial ischemia, heart failure, peripheral perfusion, or oxygenation. Options for medical therapy for patients with symptomatic MAT requiring ventricular rate control include non-dihydropyridine calcium channel blockers and beta blockers. For patients without heart failure or bronchospasm, we suggest initial therapy with a beta blocker, usually <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a>, before calcium channel blockers. Conversely, for patients with severe bronchospasm, we suggest initial therapy with a non-dihydropyridine calcium channel blocker, usually <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>, rather than a beta blocker. Beta blockers may be used cautiously in patients with stable heart failure.</p><p/><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">WIDE QRS COMPLEX TACHYARRHYTHMIAS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Discussion of the treatment of wide QRS complex tachycardias, similar to narrow QRS complex tachycardias, can be divided into those with a regular or irregular ventricular rate.</p><p class=\"headingAnchor\" id=\"H540969796\"><span class=\"h2\">Regular wide QRS complex tachyarrhythmias</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The regular wide QRS complex tachycardias include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Monomorphic ventricular tachycardia (VT) (see <a href=\"topic.htm?path=sustained-monomorphic-ventricular-tachycardia-in-patients-with-structural-heart-disease-treatment-and-prognosis\" class=\"medical medical_review\">&quot;Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis&quot;</a> and <a href=\"topic.htm?path=monomorphic-ventricular-tachycardia-in-the-absence-of-apparent-structural-heart-disease\" class=\"medical medical_review\">&quot;Monomorphic ventricular tachycardia in the absence of apparent structural heart disease&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Supraventricular tachycardia with aberrant conduction, underlying conduction delay, or conduction over an accessory pathway (eg, AVNRT with right bundle branch block)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Supraventricular tachycardia with a paced ventricular response</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antidromic AVRT</p><p/><p>The most concerning potential cause of a wide QRS complex tachycardia is VT, and, in the majority of patients, the arrhythmia should be assumed to be VT until proven otherwise.</p><p>Immediate assessment of patient stability takes precedence over any further diagnostic evaluation. (See <a href=\"topic.htm?path=approach-to-the-diagnosis-of-wide-qrs-complex-tachycardias#H39\" class=\"medical medical_review\">&quot;Approach to the diagnosis of wide QRS complex tachycardias&quot;, section on 'Summary and recommendations'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A patient who is unresponsive or pulseless should be treated according to standard advance cardiac life support (ACLS) algorithms (<a href=\"image.htm?imageKey=EM%2F73862\" class=\"graphic graphic_algorithm graphicRef73862 \">algorithm 3</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a patient who is unstable but conscious, we recommend immediate synchronized cardioversion, with conscious sedation given, if possible </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a stable patient, a focused diagnostic evaluation may proceed to determine the etiology of the arrhythmia and guide specific therapy</p><p/><p class=\"headingAnchor\" id=\"H8337612\"><span class=\"h3\">Ventricular tachycardia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In stable patients with known or presumed VT, we recommend the following approach (see <a href=\"topic.htm?path=approach-to-the-diagnosis-of-wide-qrs-complex-tachycardias#H39\" class=\"medical medical_review\">&quot;Approach to the diagnosis of wide QRS complex tachycardias&quot;, section on 'Summary and recommendations'</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend synchronized external cardioversion, following appropriate conscious sedation, as the initial therapy for most patients with stable VT. If the patient has an implantable cardioverter-defibrillator, it may be possible to terminate the arrhythmia by antitachycardia pacing prior to an attempted cardioversion.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with refractory or recurrent wide complex tachycardia (WCT), we suggest an intravenous class I or III antiarrhythmic drug (<a href=\"image.htm?imageKey=CARD%2F56600\" class=\"graphic graphic_table graphicRef56600 \">table 2</a>), such as <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a>, <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a>, or <a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">procainamide</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In selected patients known to have one of the syndromes of VT in the setting of a structurally normal heart, we suggest calcium channel blockers or beta blockers be used for arrhythmia termination or suppression. However, the decision to use these drugs in this setting should be made in consultation with a cardiologist experienced in arrhythmia management.</p><p/><p class=\"headingAnchor\" id=\"H8337725\"><span class=\"h3\">Supraventricular tachycardia with aberrant conduction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The narrow complex supraventricular tachycardia (SVT) rhythms may present with a wide complex in the setting of aberrant conduction or conduction over an accessory pathway (not including AVRT).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In stable patients with a WCT that is <strong>known</strong> to be an SVT, initial management is similar to that of an SVT with a narrow QRS complex. A continuous rhythm strip should be obtained during any intervention that is intended to slow or terminate the arrhythmia. (See <a href=\"#H1041227\" class=\"local\">'Regular narrow QRS complex tachyarrhythmias'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For AVNRT or AVRT, or an SVT in which the specific arrhythmia is <strong>unknown</strong>, we suggest the following sequence of interventions in order to terminate the arrhythmia or to slow ventricular response and facilitate diagnosis in stable patients:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Vagotonic maneuvers (eg, valsalva or carotid sinus pressure)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Intravenous <a href=\"topic.htm?path=adenosine-drug-information\" class=\"drug drug_general\">adenosine</a></p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Intravenous calcium channel blockers or beta blockers</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cardioversion in selected persistent cases, or if the patient is unstable</p><p/><p class=\"headingAnchor\" id=\"H540969885\"><span class=\"h3\">Supraventricular tachycardia with a pacemaker</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Regular wide QRS complex tachycardias in patients with a pacemaker may be due to tracking of one of the typical supraventricular tachycardias (eg, sinus tachycardia, atrial flutter, etc) or may be due to endless loop tachycardia (ELT, also referred to as pacemaker-mediated tachycardia [PMT]). (See <a href=\"topic.htm?path=unexpected-rhythms-with-normally-functioning-dual-chamber-pacing-systems#H7\" class=\"medical medical_review\">&quot;Unexpected rhythms with normally functioning dual-chamber pacing systems&quot;, section on 'Pacemaker-mediated tachycardia'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with tracking of a native supraventricular tachyarrhythmia, the pacemaker usually should automatically mode switch to a non-tracking mode. If it does not, placing a magnet on the pacemaker will lead to asynchronous pacing at a fixed and lower rate, and the pacemaker settings can be adjusted to prevent rapid pacing.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If the rhythm is due to ELT, retrograde conduction from the ventricle to the atrium is sensed by the pacemaker and serves as a trigger to pace the ventricle, which again conducts back to the atrium and perpetuates the tachycardia. Placing a magnet on the pacemaker leads to asynchronous pacing and will stop the tachycardia. Most pacemakers have algorithms to prevent or treat ELT, but pacemaker settings can usually be reprogrammed if they are ineffective.</p><p/><p class=\"headingAnchor\" id=\"H540969891\"><span class=\"h3\">Antidromic AVRT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with acute symptomatic <strong>antidromic</strong> AVRT (regular and wide QRS complex) who are hemodynamically stable, our approach is as follows (see <a href=\"topic.htm?path=treatment-of-symptomatic-arrhythmias-associated-with-the-wolff-parkinson-white-syndrome#H7\" class=\"medical medical_review\">&quot;Treatment of symptomatic arrhythmias associated with the Wolff-Parkinson-White syndrome&quot;, section on 'Acute termination of antidromic AVRT'</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We treat with intravenous <a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">procainamide</a> in an effort to terminate the tachycardia or, if the tachycardia persists, slow the ventricular response. This is because it is often difficult to correctly determine that the rhythm is due to antidromic AVRT and not ventricular tachycardia.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If the rhythm is definitely known to be antidromic AVRT, then <a href=\"topic.htm?path=adenosine-drug-information\" class=\"drug drug_general\">adenosine</a>, <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>, or IV beta blockers may be considered.</p><p/><p class=\"headingAnchor\" id=\"H540969897\"><span class=\"h2\">Irregular wide QRS complex tachyarrhythmias</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The irregular wide QRS complex tachycardias include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Polymorphic VT (see <a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology#H2\" class=\"medical medical_review\">&quot;Acquired long QT syndrome: Definitions, causes, and pathophysiology&quot;, section on 'Torsades de pointes'</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Irregular narrow complex tachycardias with aberrant conduction or underlying conduction delay (eg, atrial fibrillation with right bundle branch block)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preexcited atrial fibrillation</p><p/><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Polymorphic ventricular tachycardia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polymorphic (or polymorphous) ventricular tachycardia (VT) is defined as an unstable rhythm with a continuously varying QRS complex morphology in any recorded electrocardiographic (ECG) lead. Polymorphic VT is generally a rapid and hemodynamically unstable rhythm, and urgent defibrillation is usually necessary. In addition to immediate defibrillation, further therapy is intended to treat underlying disorders and to prevent recurrences. The specific approach depends upon whether or not the QT interval on the baseline ECG is prolonged. Polymorphic VT that occurs in the setting of QT prolongation in sinus rhythm is considered as a distinct arrhythmia, called torsades de pointes. (See <a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology#H2\" class=\"medical medical_review\">&quot;Acquired long QT syndrome: Definitions, causes, and pathophysiology&quot;, section on 'Torsades de pointes'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prompt defibrillation is indicated in patients with hemodynamically unstable torsades de pointes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the conscious patient with recurrent episodes of torsades de pointes:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Intravenous magnesium is first-line therapy, as it is highly effective for both treatment and prevention of recurrence of long QT-related ventricular ectopic beats that trigger torsades de pointes. The benefit is seen even in patients with normal serum magnesium concentrations at baseline.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Temporary transvenous overdrive pacing (atrial or ventricular) at about 100 beats per minute is generally reserved for patients who do not respond to intravenous magnesium.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In those with congenital long QT syndrome, beta blockers may be used to reduce the frequency of premature ventricular contractions and shorten the QT interval.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with polymorphic VT triggered by pauses or bradycardia, <a href=\"topic.htm?path=isoproterenol-drug-information\" class=\"drug drug_general\">isoproterenol</a> (initial dose 0.05 to 0.1 <span class=\"nowrap\">mcg/kg</span> per minute in children and 2 <span class=\"nowrap\">mcg/minute</span> in adults, then titrated to achieve a heart rate of 100 beats per minute) can be used as a temporizing measure to achieve a heart rate of 100 beats per minute prior to pacing.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with polymorphic VT and a normal baseline QT interval, the most likely cause is myocardial ischemia. Treatments may include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Prompt defibrillation in the hemodynamically unstable patient.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Beta-blockers if blood pressure tolerates. <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">Metoprolol</a> 5 mg intravenously every five minutes, to a total of 15 mg, may be given.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>IV <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a> may prevent a recurrent episode.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Urgent coronary angiography and possible revascularization.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Intra-aortic balloon pump.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Magnesium is less likely to be effective for polymorphic VT if the baseline QT interval is normal.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If the polymorphic VT is due to catecholaminergic polymorphic ventricular tachycardia (CPVT), beta blockers should be used. If it is due to Brugada syndrome, <a href=\"topic.htm?path=isoproterenol-drug-information\" class=\"drug drug_general\">isoproterenol</a> should be initiated. (See <a href=\"topic.htm?path=catecholaminergic-polymorphic-ventricular-tachycardia-and-other-polymorphic-ventricular-tachycardias-with-a-normal-qt-interval#H10798824\" class=\"medical medical_review\">&quot;Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval&quot;, section on 'Acute management'</a> and <a href=\"topic.htm?path=brugada-syndrome-prognosis-management-and-approach-to-screening\" class=\"medical medical_review\">&quot;Brugada syndrome: Prognosis, management, and approach to screening&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H540969952\"><span class=\"h3\">Preexcited atrial fibrillation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with acute symptomatic preexcited atrial fibrillation who are hemodynamically stable, our approach is as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest initial medical therapy with rhythm control versus rate control. While there is no clear first-line medication for rhythm control, options include <a href=\"topic.htm?path=ibutilide-drug-information\" class=\"drug drug_general\">ibutilide</a> and <a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">procainamide</a>. (See <a href=\"topic.htm?path=treatment-of-symptomatic-arrhythmias-associated-with-the-wolff-parkinson-white-syndrome#H10\" class=\"medical medical_review\">&quot;Treatment of symptomatic arrhythmias associated with the Wolff-Parkinson-White syndrome&quot;, section on 'Acute treatment of atrial fibrillation with preexcitation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For all patients with preexcited atrial fibrillation, we recommend <strong>not</strong> using standard AV nodal blocking medications (ie, beta blockers, non-dihydropyridine calcium channel blockers [<a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a> and <a href=\"topic.htm?path=diltiazem-drug-information\" class=\"drug drug_general\">diltiazem</a>], <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">digoxin</a>, <a href=\"topic.htm?path=adenosine-drug-information\" class=\"drug drug_general\">adenosine</a>, <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a>). Blocking the AV node may result in increased conduction of atrial impulses to the ventricle by way of the accessory pathway, increasing the ventricular rate and potentially resulting in hemodynamic instability and development of ventricular fibrillation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>While preexcited atrial fibrillation conducts down a bypass pathway, in contrast to AVRT, the rhythm is irregularly irregular and wide complex.</p><p/><p class=\"headingAnchor\" id=\"H1534999366\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-atrial-fibrillation\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Atrial fibrillation&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-arrhythmias-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Arrhythmias in adults&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-ventricular-arrhythmias\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Ventricular arrhythmias&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-basic-and-advanced-cardiac-life-support-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Basic and advanced cardiac life support in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=tachycardia-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Tachycardia (The Basics)&quot;</a> and <a href=\"topic.htm?path=ventricular-tachycardia-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Ventricular tachycardia (The Basics)&quot;</a> and <a href=\"topic.htm?path=supraventricular-tachycardia-svt-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Supraventricular tachycardia (SVT) (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H5231327\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For hemodynamically unstable patients, urgent cardioversion should be performed.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Further treatment recommendations regarding the acute management of tachyarrhythmias are presented throughout this topic.</p><p/><p class=\"headingAnchor\" id=\"H540970087\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The authors and UpToDate would like to thank Dr. Philip Podrid and Dr. Leonard Ganz, who contributed to earlier versions of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/overview-of-the-acute-management-of-tachyarrhythmias/abstract/1\" class=\"nounderline abstract_t\">Link MS. Clinical practice. Evaluation and initial treatment of supraventricular tachycardia. N Engl J Med 2012; 367:1438.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-the-acute-management-of-tachyarrhythmias/abstract/2\" class=\"nounderline abstract_t\">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2016; 67:e27.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-the-acute-management-of-tachyarrhythmias/abstract/3\" class=\"nounderline abstract_t\">Kalbfleisch SJ, el-Atassi R, Calkins H, et al. Differentiation of paroxysmal narrow QRS complex tachycardias using the 12-lead electrocardiogram. J Am Coll Cardiol 1993; 21:85.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 936 Version 23.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H5231327\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H1040743\" id=\"outline-link-H1040743\">INITIAL DIAGNOSTIC AND TREATMENT DECISIONS</a><ul><li><a href=\"#H1040751\" id=\"outline-link-H1040751\">Is the patient clinically (or hemodynamically) unstable?</a></li><li><a href=\"#H1040758\" id=\"outline-link-H1040758\">Is the QRS complex narrow or wide? Regular or irregular?</a></li></ul></li><li><a href=\"#H1041109\" id=\"outline-link-H1041109\">NARROW QRS COMPLEX TACHYARRHYTHMIAS</a><ul><li><a href=\"#H1041227\" id=\"outline-link-H1041227\">Regular narrow QRS complex tachyarrhythmias</a><ul><li><a href=\"#H30456082\" id=\"outline-link-H30456082\">- Sinus tachycardia</a></li><li><a href=\"#H30456175\" id=\"outline-link-H30456175\">- Atrioventricular nodal reentrant tachycardia (AVNRT)</a></li><li><a href=\"#H30456182\" id=\"outline-link-H30456182\">- Atrioventricular reentrant tachycardia (AVRT)</a></li><li><a href=\"#H30456218\" id=\"outline-link-H30456218\">- Atrial tachycardia</a></li><li><a href=\"#H540969608\" id=\"outline-link-H540969608\">- Atrial flutter</a></li></ul></li><li><a href=\"#H30456299\" id=\"outline-link-H30456299\">Irregular narrow QRS complex tachyarrhythmias</a><ul><li><a href=\"#H8336616\" id=\"outline-link-H8336616\">- Atrial fibrillation</a></li><li><a href=\"#H636766958\" id=\"outline-link-H636766958\">- Atrial flutter</a></li><li><a href=\"#H8336630\" id=\"outline-link-H8336630\">- Multifocal atrial tachycardia</a></li></ul></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">WIDE QRS COMPLEX TACHYARRHYTHMIAS</a><ul><li><a href=\"#H540969796\" id=\"outline-link-H540969796\">Regular wide QRS complex tachyarrhythmias</a><ul><li><a href=\"#H8337612\" id=\"outline-link-H8337612\">- Ventricular tachycardia</a></li><li><a href=\"#H8337725\" id=\"outline-link-H8337725\">- Supraventricular tachycardia with aberrant conduction</a></li><li><a href=\"#H540969885\" id=\"outline-link-H540969885\">- Supraventricular tachycardia with a pacemaker</a></li><li><a href=\"#H540969891\" id=\"outline-link-H540969891\">- Antidromic AVRT</a></li></ul></li><li><a href=\"#H540969897\" id=\"outline-link-H540969897\">Irregular wide QRS complex tachyarrhythmias</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">- Polymorphic ventricular tachycardia</a></li><li><a href=\"#H540969952\" id=\"outline-link-H540969952\">- Preexcited atrial fibrillation</a></li></ul></li></ul></li><li><a href=\"#H1534999366\" id=\"outline-link-H1534999366\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H29640071\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H5231327\" id=\"outline-link-H5231327\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H540970087\" id=\"outline-link-H540970087\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/936|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=CARD/109811\" class=\"graphic graphic_algorithm\">- Evaluation narrow QRS complex tachycardias in unstable patients</a></li><li><a href=\"image.htm?imageKey=CARD/76920\" class=\"graphic graphic_algorithm\">- Evaluation narrow QRS complex tachycardias in stable patients</a></li><li><a href=\"image.htm?imageKey=EM/73862\" class=\"graphic graphic_algorithm\">- Adult cardiac arrest algorithm</a></li></ul></li><li><div id=\"CARD/936|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/62762\" class=\"graphic graphic_table\">- Drug Rx arrhythmias WPW</a></li><li><a href=\"image.htm?imageKey=CARD/56600\" class=\"graphic graphic_table\">- Vaughan Williams classification of antiarrhythmic drugs</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology\" class=\"medical medical_review\">Acquired long QT syndrome: Definitions, causes, and pathophysiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-myocardial-infarction-role-of-beta-blocker-therapy\" class=\"medical medical_review\">Acute myocardial infarction: Role of beta blocker therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-diagnosis-of-wide-qrs-complex-tachycardias\" class=\"medical medical_review\">Approach to the diagnosis of wide QRS complex tachycardias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atrial-fibrillation-risk-of-embolization\" class=\"medical medical_review\">Atrial fibrillation: Risk of embolization</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atrioventricular-nodal-reentrant-tachycardia\" class=\"medical medical_review\">Atrioventricular nodal reentrant tachycardia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atrioventricular-reentrant-tachycardia-avrt-associated-with-an-accessory-pathway\" class=\"medical medical_review\">Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=basic-principles-and-technique-of-electrical-cardioversion-and-defibrillation\" class=\"medical medical_review\">Basic principles and technique of electrical cardioversion and defibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=brugada-syndrome-prognosis-management-and-approach-to-screening\" class=\"medical medical_review\">Brugada syndrome: Prognosis, management, and approach to screening</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=catecholaminergic-polymorphic-ventricular-tachycardia-and-other-polymorphic-ventricular-tachycardias-with-a-normal-qt-interval\" class=\"medical medical_review\">Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-evaluation-of-narrow-qrs-complex-tachycardias\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=focal-atrial-tachycardia\" class=\"medical medical_review\">Focal atrial tachycardia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intraatrial-reentrant-tachycardia\" class=\"medical medical_review\">Intraatrial reentrant tachycardia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-new-onset-atrial-fibrillation\" class=\"medical medical_review\">Management of new onset atrial fibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-management-of-symptomatic-aortic-stenosis\" class=\"medical medical_review\">Medical management of symptomatic aortic stenosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=monomorphic-ventricular-tachycardia-in-the-absence-of-apparent-structural-heart-disease\" class=\"medical medical_review\">Monomorphic ventricular tachycardia in the absence of apparent structural heart disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=multifocal-atrial-tachycardia\" class=\"medical medical_review\">Multifocal atrial tachycardia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-atrial-fibrillation\" class=\"medical medical_review\">Overview of atrial fibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-atrial-flutter\" class=\"medical medical_review\">Overview of atrial flutter</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=supraventricular-tachycardia-svt-the-basics\" class=\"medical medical_basics\">Patient education: Supraventricular tachycardia (SVT) (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tachycardia-the-basics\" class=\"medical medical_basics\">Patient education: Tachycardia (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ventricular-tachycardia-the-basics\" class=\"medical medical_basics\">Patient education: Ventricular tachycardia (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sinoatrial-nodal-reentrant-tachycardia-sanrt\" class=\"medical medical_review\">Sinoatrial nodal reentrant tachycardia (SANRT)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sinus-tachycardia-evaluation-and-management\" class=\"medical medical_review\">Sinus tachycardia: Evaluation and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-arrhythmias-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Arrhythmias in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-atrial-fibrillation\" class=\"medical medical_society_guidelines\">Society guideline links: Atrial fibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-basic-and-advanced-cardiac-life-support-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Basic and advanced cardiac life support in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-ventricular-arrhythmias\" class=\"medical medical_society_guidelines\">Society guideline links: Ventricular arrhythmias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sustained-monomorphic-ventricular-tachycardia-in-patients-with-structural-heart-disease-treatment-and-prognosis\" class=\"medical medical_review\">Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-symptomatic-arrhythmias-associated-with-the-wolff-parkinson-white-syndrome\" class=\"medical medical_review\">Treatment of symptomatic arrhythmias associated with the Wolff-Parkinson-White syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unexpected-rhythms-with-normally-functioning-dual-chamber-pacing-systems\" class=\"medical medical_review\">Unexpected rhythms with normally functioning dual-chamber pacing systems</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vagal-maneuvers\" class=\"medical medical_review\">Vagal maneuvers</a></li></ul></div></div>","javascript":null}